Jose Lucar, MD, is an infectious disease physician and associate professor of medicine in the Division of Infectious Diseases at the George Washington University (GW) School of Medicine and Health Sciences and the GW Medical Faculty Associates. After earning his medical degree from the Universidad Peruana Cayetano Heredia in Lima, Peru, he completed his internal medicine residency training at the Georgetown University Hospital – Washington Hospital Center program in 2014. Two years later, he completed his infectious diseases fellowship at GW. In 2016, he joined the Division of Infectious Diseases at the University of Mississippi Medical Center. There, he served as the medical director of the outpatient parenteral antimicrobial program until his return to GW in 2021. Dr. Lucar now serves as the medical director of GW Hospital's antimicrobial stewardship program. He is board certified in internal medicine and infectious diseases by the American Board of Internal Medicine, and in 2022 he was elected a Fellow of the Infectious Diseases Society of America. His clinical and research interests include mycobacterial infections, HIV treatment and prevention, infections in immunocompromised hosts, and emerging infectious diseases.
This is a phase 3 open label, multi-center, randomized, active-controlled non-inferiority trial that compares the safety and effectiveness of a 6-week regimen of daily rifapentine against the current standard of 12-16 weeks of rifamycin-based treatment for latent TB infection (LTBI).